OptiScan Biomedical has received CE mark approval for its OptiScanner Automatic Bedside Glucose Monitoring System to commercialize the product in European Economic Area (EEA) comprising 30 countries.

OptiScanner bedside glucose monitoring system provides continuous monitoring of patients’ glucose levels measured in plasma, as opposed to whole blood.

The system displays glucose level trend data updated every 15 minutes to help manage patients’ glucose levels within an optimum target range.

OptiScan Biomedical chairman and CEO Peter Rule said they look forward to continue their development and regulatory efforts to secure approval and introduce the OptiScanner in Europe, the US and other countries.

"we’re focused on next-generation products that can bring even greater capabilities and benefits to physicians and patients in the ICU," Rule said.